Table 3: Highlights of MSC therapy outcomes from published clinical trial reports (Jan., 2011- Mar., 2016).

 

MSC source

Indication

Phase

No. of patients

Route of administration

Outcome

References

Auto-BMSC

ALS

I

19

Intrathecal

Safe

[74]

Auto-BMSC

ALS

I

7

Intrathecal

Safe

[75]

Auto-BMSC

Spinal cord injury

I/II

11

Lumbar puncture

Safe, variable improvement

[76]

Auto-BMSC

Spinal cord injury

I

14

Intra-lesional

Safe, variable improvement

[77]

Auto-BMSC

Degenerative disc disease

I

10

Intra-nucleus pulposus

Rapidly improved

[78]

Auto-BMSC

Coronary artery disease

I/II

31

Intra-myocardium

Safe, significantly improved

[79]

Auto-BMSC

Acute myocardial infarction

II/III

58

Intra-coronary

Safe, modestly improved

[80]

Auto-BMSC

Alcoholic liver cirrhosis

II

11

IV

Safe, improved

[81]

Auto-BMSC

HCV-induced cirrhosis

II

15

IV

Safe, partially improved

[82]

Auto-BMSC

MS

II

5

IV

Safe

[83]

Auto-BMSC

MS

I/II

10

IV

Safe, improved

[84,85]

Auto-BMSC

OA, knee

I/II

12

Intra-articular

Safe, significantly improved

[86]

Auto-BMSC

Kidney allograft

I

6

IV

Safe, improved

[87]

Auto-BMSC& BMNCs

Critical limb ischemia

II

26

Intramuscular

Safe, significantly improved

[88]

Auto-BMSC/ MSC

Ischemic cardiomyopathy

I/II

65

Transendocardium

Safe

[89]

Auto-/Allo-BMSC

Ischemic cardiomyopathy

I/II

30

Transendocardium

Safe, improved

[90]

Auto-AMSC

Crohn’s disease

II

41

Intra-fistula tract

Safe, improved

[91]

Auto-AMSC

Idiopathic pulmonary fibrosis

I

14

Intra-endobronchial

Safe

[92]

Auto-AMSC

OA, knee

I/II

18

Intra-articular

Safe, improved

[93]

Auto-AMSC

Anal fistula

III

124

Intra-fistula tract

Safe, improved

[94]

Auto-MSC

Spinal cord injury

III

16

Intramedullary/Intradural space

Safe, weak efficacy

[95]

Allo-BMSC

SLE

I/II

15

IV

Improved

[96,97]

Allo-BMSC

ARDS

I

9

IV

Safe

[98]

Allo-BMSC

Critical limb ischemia

I/II

20

Intramuscular

Safe, improved

[99]

Allo-BMSC

OA, knee

I/II

30

Intra-articular

Safe, significantly improved

[100]

Allo-BMSC

aGvHD

II

25

IV

Safe

[101]

Allo-BMSC

GvHD

II

37

IV

Safe, improved

[102]

Allo-BMSC

GvHD

I

40 (15 children)

IV

Safe, variable improvements

[25]

Allo-BMSC (JR-031)

aGvHD

II/III

25

IV

Variable improvements

[103]

Allo-UCMSC

SLE

I/II

40

IV

Variable improvements

[97,104]

Allo-UCB-MSC

BPD (Preterm)

I

9 (preterm infants)

Intratracheal

Safe

[105]

Allo-UCB-MSC

Critical limb ischemia

I

8

Intramuscular

Safe

[106]

Allo-UCB-MNCs/ UCMSC

Autism

I/II

23

IV + Intrathecal

Safe, improved

[107]

Allo-PL-MSC

Idiopathic pulmonary fibrosis

I

8

IV

Safe

[108]

Allo-PL-MSC (PDA-001)

MS

I

16

IV

Safe

[109]

Allo-MPCs

Nonischemic heart failure

II

60

Transendocardium

Safe

[110]

Allo-MPACs

aGvHD

I

36

IV

Safe

[111]

Allo-MSC

Crohn’s disease

II

15

IV

Variable improvements

[112]

Allo-MSC

GvHD

I/II

18

IV

Variable improvements

[113]

Allo-MSC (Prochymal)

aGvHD

I

12 (children)

IV

Safe, variable improvements

[114]

Allo-AMSC

Crohn’s disease

I/II

24

Intra-lesional

Safe, improved

[115]

Allo-WJ-MSC

Type 2 diabetes mellitus

I/II

22

IV + Intrapancreatic endovascular injections

Safe, improved

[116]

Lxmyelocel-T

Critical limb ischemia

II

72

Leg injections

Safe, prolonged treatment failure

[117]

 

Abbreviations: Allo: allogeneic; Auto: autologous; AMSC: adipose tissue-derived mesenchymal stem cells; BMSC: bone marrow-derived mesenchymal stem cells; MSC: mesenchymal stem cells; MNCs: mononuclear cells; MPCs: mesenchymal progenitor cells; MPACs: multipotent adult progenitor cells; UC-: umbilical cord-derived; UCB-: umbilical cord blood-derived; PL-: placenta-derived; WJ-: Wharton’s jelly-derived; ALS: amyotrophic lateral sclerosis; ARDS: acute respiratory distress syndrome; BPD: bronchopulmonary dysplasia; MS: multiple sclerosis; OA: osteoarthritis; SLE: systemic lupus erythematosus; aGvHD: acute graft-versus-host disease; IV: intravenous; HCV: hepatitis C virus